首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador)
【2h】

Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador)

机译:来自已发表的前瞻性对照队列研究对槲寄生制剂对乳腺癌患者的长期治疗的生存和心身自我调节的个体患者数据荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Mistletoe preparations such as Iscador are in common use as complementary/anthroposophic medications for many cancer indications, particularly for solid cancers. The efficacy is still discussed controversially. This paper presents an individual patient data meta-analysis of all published prospective matched-pair studies with breast cancer patients concerned with long-term application of a complementary/anthroposophic therapy with the mistletoe preparation Iscador. Six sets of data were available for individual patient meta-analysis of breast cancer patients, matched according to prognostic factors into pairs with and without mistletoe (Iscador) therapy. The main outcome measures were overall survival and psychosomatic self-regulation. Overall survival was almost significant in favor of the Iscador group in the combined data set of the randomized studies: estimate of the hazard ratio with 95% confidence interval 0.59 (0.34, 1.02). Overall survival was highly significant in the combined data set of the non-randomized studies: 0.43 (0.34, 0.56). In the combined analysis of the randomized studies, improvement of psychosomatic self-regulation, as a measure of autonomous coping with the disease, was highly significant in favor of the Iscador group: estimate of the median difference 0.45 (0.15, 0.80), P = 0.0051. The analyzed studies show that therapy with Iscador might prolong overall survival and improve psychosomatic self-regulation of breast cancer patients.
机译:槲寄生制剂(例如Iscador)通常用作许多癌症适应症(尤其是实体癌)的补充/人类营养药物。疗效仍存在争议。本文介绍了所有长期发表的关于乳腺癌患者的前瞻性配对研究的个人数据荟萃分析,这些研究涉及槲寄生制剂Iscador长期应用补充/拟人疗法。六组数据可用于乳腺癌患者的个体患者荟萃分析,根据预后因素将配对和不配对槲寄生(Iscador)治疗配对。主要结局指标是总体生存率和心身自我调节。在随机研究的组合数据集中,总体生存率几乎对Iscador组有利:估计95%置信区间为0.59(0.34,1.02)的危险比。在非随机研究的组合数据集中,总体生存率非常重要:0.43(0.34,0.56)。在对随机研究的综合分析中,心身自我调节的改善作为一种自主应对疾病的方法,对Iscador组非常重要:中位数差异的估计值为0.45(0.15,0.80),P = 0.0051。分析的研究表明,Iscador疗法可延长乳腺癌患者的总体生存率并改善其心身自我调节能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号